Company intelligence / Profile preview

Synagen AI

Berlin, Berlin, Germanysynagen.ai ↗

Ownership: Private
Development stage: Other

Overview

Synagen AI develops advanced artificial intelligence agents designed to enhance diagnostics, clinical workflows, evidence-based decision-making, and accelerate scientific discoveries in healthcare—especially oncology. Their solutions integrate with existing systems to provide actionable insights for clinicians and researchers. The company collaborates with leading institutions to ensure real-world impact but does not appear to have its own clinical-stage therapeutic assets as of June 2025.

Therapeutic areas: Oncology
Modalities: Not directly applicable
Industry: Digital Health Medical Devices

Partnerships

Collaborations with leading healthcare institutions, research facilities, and industry pioneers

Beyond the preview

Go deeper on Synagen AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synagen AI.

Explore the full profile